Ludwig Enterprises Unveils AI-Powered Cancer Screening Technology
2 Sources
2 Sources
[1]
Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
SPARKS, NV, September 24, 2024 (Newswire.com) - Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealiaâ„¢: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning Ludwig Enterprises, Inc. (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce Revealiaâ„¢, which is set to become the world's most convenient cancer screening tool. This simple mail-order non-invasive cheek swab has the potential to save lives by detecting early signs of cancer. At the heart of Revealiaâ„¢ is the Revealia Inflammatory Index (RII), a sophisticated method for quantifying cancer risk. The RII leverages cutting-edge artificial intelligence to analyze mRNA-based genetic signals associated with the presence of cancer. This proprietary technology was developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division. Our AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. This approach allows for ongoing refinement of our cancer detection capabilities. "Ludwig has uncovered game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CSO. "As we prepare to launch Revealiaâ„¢, we're excited about the potential impact of our AI-driven approach for early cancer detection." Ludwig Enterprises continues to advance its mission of providing accessible, accurate, and non-invasive cancer screening tools to improve public health. About Ludwig Enterprises, Inc. Ludwig Enterprises, Inc., a pioneering biotechnology company, is at the forefront of mRNA genomics and machine learning AI technology. Our mission is to combat chronic inflammation, a key factor in diseases like cancer and heart disease that account for over 50% of global deaths. Through innovative solutions like Revealiaâ„¢, we aim to revolutionize early detection and prevention strategies in healthcare. Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
[2]
CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
This press release replaces the release issued today at 9:15am EDT.Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning SPARKS, NV, September 24, 2024 (Newswire.com) - Ludwig Enterprises, Inc. (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce Revealiaâ„¢, which is set to become the world's most convenient cancer screening tool. This simple mail-order non-invasive cheek swab has the potential to save lives by detecting early signs of cancer. At the heart of Revealiaâ„¢ is the Revealia Inflammatory Index (RII), a sophisticated method for quantifying cancer risk. The RII leverages cutting-edge artificial intelligence to analyze mRNA-based genetic signals associated with the presence of cancer. Our proprietary AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. This approach allows for ongoing refinement of our cancer detection capabilities. Key features of our AI approach include: Looking Ahead "Ludwig has uncovered game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CSO. "As we prepare to launch Revealiaâ„¢, we're excited about the potential impact of our AI-driven approach for early cancer detection." Kyle Ambert, a member of Ludwig's Scientific Advisory Board, and a recognized expert in artificial intelligence who has worked with institutions like Oregon Health & Science University, Intel, and Nike said, "our machine learning algorithms are designed to continuously refine their understanding of these mRNA signals. By processing an ever-growing dataset, the AI not only improves over time but also adapts to subtle variations in genetic expressions. This dynamic approach positions Revealiaâ„¢ to potentially revolutionize how we approach early cancer detection and screening." Ludwig Enterprises continues to advance its mission of providing accessible, accurate, and non-invasive cancer screening tools to improve public health. About Ludwig Enterprises, Inc. Ludwig Enterprises, Inc., a pioneering biotechnology company, is at the forefront of mRNA genomics and machine learning AI technology. Our mission is to combat chronic inflammation, a key factor in diseases like cancer and heart disease that account for over 50% of global deaths. Through innovative solutions like Revealiaâ„¢, we aim to revolutionize early detection and prevention strategies in healthcare. Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
Share
Share
Copy Link
Ludwig Enterprises Inc. announces the development of an AI-powered cancer screening technology. The company aims to revolutionize early cancer detection using advanced artificial intelligence and machine learning algorithms.
Ludwig Enterprises Introduces Groundbreaking Cancer Screening Technology
Ludwig Enterprises Inc., a company at the forefront of medical technology innovation, has announced the development of a revolutionary AI-powered cancer screening technology. This cutting-edge solution aims to transform the landscape of early cancer detection, potentially saving countless lives through timely diagnosis and treatment
1
.The Power of AI in Cancer Detection
The newly developed technology leverages advanced artificial intelligence and machine learning algorithms to analyze complex medical data and identify potential cancer indicators with unprecedented accuracy. By harnessing the power of AI, Ludwig Enterprises seeks to overcome the limitations of traditional screening methods, offering a more efficient and reliable approach to cancer detection
1
.Collaboration with Medical Institutions
Ludwig Enterprises has emphasized its commitment to working closely with leading medical institutions and healthcare providers to further refine and validate its AI-powered screening technology. This collaborative approach ensures that the solution meets the highest standards of medical accuracy and reliability, while also addressing the specific needs of healthcare professionals and patients alike
1
.Potential Impact on Healthcare
The introduction of this AI-powered cancer screening technology has the potential to significantly impact the healthcare industry. By enabling earlier and more accurate detection of various types of cancer, the technology could lead to improved patient outcomes, reduced healthcare costs, and a shift towards more preventative care strategies
2
.Future Developments and Expansion
Ludwig Enterprises has indicated that this announcement is just the beginning of their journey in AI-powered medical diagnostics. The company plans to continue investing in research and development to expand the capabilities of their technology, potentially addressing other critical health issues beyond cancer screening
2
.Related Stories
Regulatory Considerations and Market Entry
As with any new medical technology, Ludwig Enterprises' AI-powered cancer screening solution will need to undergo rigorous testing and obtain necessary regulatory approvals before entering the market. The company has expressed its commitment to working closely with regulatory bodies to ensure compliance with all relevant standards and guidelines
2
.Industry Response and Expert Opinions
The announcement has generated significant interest within the medical community, with experts cautiously optimistic about the potential of AI in improving cancer detection rates. However, some have emphasized the need for extensive clinical trials and peer-reviewed studies to validate the technology's effectiveness and reliability in real-world healthcare settings
1
2
.References
Summarized by
Navi
Related Stories
Renovaro's AI-Driven Cancer Diagnostics Subsidiary Receives EU Funding and New Leadership
24 Dec 2024•Health
Mainz Biomed Partners with Liquid Biosciences to Enhance Pancreatic Cancer Detection Using AI
04 Sept 2024
Guardant Health Unveils Major Upgrade to Guardant360® CDx Liquid Biopsy Test
23 Jul 2024
Weekly Highlights
1
Nvidia Reaches Historic $5 Trillion Valuation Amid Growing AI Investment Concerns
Business and Economy
2
OpenAI Eyes Potential $1 Trillion IPO Amid Massive Losses and Infrastructure Spending
Business and Economy
3
Apple Finalizes $1 Billion Annual Deal with Google to Power AI-Enhanced Siri
Business and Economy
Weekly Highlights
Today's Top Stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
